Louise Chen
Stock Analyst at Scotiabank
(3.25)
# 1,083
Out of 5,115 analysts
297
Total ratings
46.98%
Success rate
2.35%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $34.08 | +17.37% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $227.25 | +16.61% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $55.05 | +8.99% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $110.27 | +8.82% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $741.45 | +3.85% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $20.34 | +293.31% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.51 | +156.41% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $28.16 | -50.28% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.80 | +566.67% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $20.00 | +175.00% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $75.53 | -27.18% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $3.79 | +295.78% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $76.80 | -34.90% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $7.69 | +95.06% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $35.91 | -52.66% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.57 | -3.54% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $17.89 | +179.49% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.99 | +200.30% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $16.60 | +231.33% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.19 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $59.43 | +169.22% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $53.57 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $223.01 | +7.62% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.44 | +70.20% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.00 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.62 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,037.15 | -14.67% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.69 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.00 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.25 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.78 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.57 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.63 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.92 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.83 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.71 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.48 | +1,767.82% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.42 | +106.61% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.00 | +233.33% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $25.37 | +97.08% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.16 | +131.48% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.57 | +1,489.83% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.67 | +250,148,135.99% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $254.36 | +1.43% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.32 | +3,687.88% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.26 | +1,487.30% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.36 | +438.28% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $34.08
Upside: +17.37%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $227.25
Upside: +16.61%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $55.05
Upside: +8.99%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $110.27
Upside: +8.82%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $741.45
Upside: +3.85%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $20.34
Upside: +293.31%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.51
Upside: +156.41%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $28.16
Upside: -50.28%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.80
Upside: +566.67%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.00
Upside: +175.00%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $75.53
Upside: -27.18%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.79
Upside: +295.78%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $76.80
Upside: -34.90%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $7.69
Upside: +95.06%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $35.91
Upside: -52.66%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.57
Upside: -3.54%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $17.89
Upside: +179.49%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.99
Upside: +200.30%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $16.60
Upside: +231.33%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.19
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $59.43
Upside: +169.22%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $53.57
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $223.01
Upside: +7.62%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.44
Upside: +70.20%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.00
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.62
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,037.15
Upside: -14.67%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.69
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.00
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.25
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.78
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.57
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.63
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.92
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.83
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.71
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.48
Upside: +1,767.82%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.42
Upside: +106.61%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.00
Upside: +233.33%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $25.37
Upside: +97.08%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.16
Upside: +131.48%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.57
Upside: +1,489.83%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.67
Upside: +250,148,135.99%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $254.36
Upside: +1.43%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.32
Upside: +3,687.88%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.26
Upside: +1,487.30%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $8.36
Upside: +438.28%